as of 12-05-2025 2:33pm EST
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | VIENNA |
| Market Cap: | 53.1M | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 61.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.98 - $32.70 | Next Earning Date: | 01-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Executive Officer
Avg Cost/Share
$5.96
Shares
8,389
Total Value
$49,998.44
Owned After
81,794
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KERSTEN GEERT R | CVM | Chief Executive Officer | Dec 4, 2025 | Buy | $5.96 | 8,389 | $49,998.44 | 81,794 |
See how CVM stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.